{"id":835409,"date":"2025-04-09T07:43:07","date_gmt":"2025-04-09T11:43:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/"},"modified":"2025-04-09T07:43:07","modified_gmt":"2025-04-09T11:43:07","slug":"os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/","title":{"rendered":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistsquare { list-style-type: square }\n.bwmarginl1 { margin-left: 30px }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals<\/b><\/p>\n<ul class=\"bwlistsquare\">\n<li><i>Company now listeria-based cancer immunotherapy world leader<\/i><\/li>\n<li><i>Expands clinical pipeline with 3 new cancer immunotherapy candidates<\/i><\/li>\n<li><i>8 pre-clinical immunotherapy candidates targeting 30+ cancers added<\/i><\/li>\n<\/ul>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nOS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of the Company\u2019s lead asset OST-HER2 in the prevention of recurrence in fully-resected, lung metastatic osteosarcoma targeted for year-end 2025. New manufacturing-based intellectual property protects the listeria-based immunotherapy platform and cancer immunotherapy candidates into 2040.\n<\/p>\n<p>\n\u201cWe are thrilled to have now consolidated all of the intellectual property for the listeria cancer immunotherapy platform into OS Therapies, positioning us to fully expand it in the years ahead and improve the standard of care across cancer treatment in the years ahead,\u201d said Paul Romness, CEO of OS Therapies. \u201cWe now have late-stage, mid-stage and early-stage cancer immunotherapy candidates, a rich pipeline of preclinical cancer immunotherapy candidates and a long IP runway to in order to fully leverage this powerful cancer immunotherapy platform.\u201d\n<\/p>\n<p>\nA video explaining how the listeria platform works is available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DxtsFVMkdsc8&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=82bdfa8e3d38725baf53b87e8b0337d1\">here<\/a>.\n<\/p>\n<p><i><span class=\"bwuline\">Clinical-stage Cancer Immunotherapy Programs Acquired<\/span><\/i><\/p>\n<ol class=\"bwlistdecimal\">\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Df2vMUedrKHU&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=OST-AXAL+%28previously+AXAL%2FADXS%2FHPV%29+for+Human+Papilloma+Virus+%28HPV%29&amp;index=2&amp;md5=52b4520542c145b3af441afbc1cd7f2f\">OST-AXAL (previously AXAL\/ADXS\/HPV) for Human Papilloma Virus (HPV)<\/a> associated cancers completed 1<sup>st<\/sup> (AIM2CERV) of 2 Phase 3 trials;\n<\/li>\n<li>\nOST-503 (previously ADXS-503) for Non-Small Cell Lung Cancer (NSCLC) &amp; Glioblastoma reported positive Phase 2 data in NSCLC;\n<\/li>\n<li>\nOST-PSA (previously ADXS-504\/ADXS31142) for Prostate Cancer.\n<\/li>\n<\/ol>\n<p><i><span class=\"bwuline\">Pre-clinical Cancer Immunotherapy Programs Acquired<\/span><\/i><\/p>\n<p class=\"bwmarginl1\">\n8 un-named OST-HOT Listeria constructs designed for off-the shelf treatment of common cancers with shared hotspot mutations and cancer-testes antigen targets.\n<\/p>\n<p>\n\u201cThe listeria cancer immunotherapy platform holds tremendous potential to improve the outcomes for cancer patients worldwide\u201d said Dr. Robert Petit, Chief Medical &amp; Scientific Officer of OS Therapies. \u201cImmune-checkpoint inhibitors have revolutionized cancer treatment in settings where tumor antigens have generated a sufficient T cell response. However, in many cancers these treatments don\u2019t help because T cell responses against key tumor antigens have not developed. The OST Listeria platform specifically delivers relevant cancer targets directly to the immune system and generates new T cell responses that can be used to fight these cancers and help eliminate metastases. With OST-HER2 and the rest of the listeria platform, we have the potential to generate novel, more potent immune and targeted immune responses against solid tumors, metastatic disease and micro metastases from early-stage to late-stage cancers. I am thrilled to be able to guide the OST-HER2 asset through approval in osteosarcoma, and then fully explore that listeria platform\u2019s potential to improve treatment outcomes for cancer patients.\u201d\n<\/p>\n<p>\nThe global cancer immunotherapy market size was valued at $126 billion in 2023 and is projected to surpass around $296 billion by 2033, according to <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.novaoneadvisor.com%2Freport%2Fcancer-immunotherapy-market&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=Nova+One+Advisor&amp;index=3&amp;md5=ed44a40877627cce16b5e888b61f029a\">Nova One Advisor<\/a>.\n<\/p>\n<p><b>About OS Therapies<\/b><\/p>\n<p>\nOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma. OST-HER2, the Company&#8217;s lead asset, is the first in a new class of immunotherapy leveraging the immune-stimulatory effects of <i>Listeria<\/i> monocytogenes to initiate a strong immune response targeting to specific cancer antigens. The Company\u2019s lead asset OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food &amp; Drug Administration. OST-HER2 demonstrated positive data in a Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma and intends to submit a BLA Accelerated Approval request to the US FDA in the third quarter of 2025. Upon approval, the Company will become eligible to receive a Priority Review Voucher, currently valued at $150 million. OST-HER2 has completed a preclinical and clinical Phase 1 clinical study primarily in breast cancer patients. An animal OST-HER2 product candidate is indicated for the treatment of canine osteosarcoma and previously received conditional approval by the U.S. Department of Agriculture for the treatment of canine osteosarcoma.\n<\/p>\n<p>\nIn addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as <i>tunable ADC<\/i> (tADC), which features tunable, tailored antibody-linker-payload candidates through its wholly-owned subsidiary OS Drug Candidates. This platform leverages the Company&#8217;s proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ostherapies.com%2F&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=www.ostherapies.com&amp;index=4&amp;md5=95e7e55317096a7950dde095bc867f92\">www.ostherapies.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should&#8221; or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in the Company\u2019s registration statement on Form S-1 filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250409331328\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250409331328\/en\/<\/a><\/span><\/p>\n<p><b>OS Therapies Contact Information:<\/p>\n<p><\/b>Jack Doll<br \/>\n<br \/>410-297-7793<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Irpr@ostherapies.com\">Irpr@ostherapies.com<br \/>\n<\/a><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FOSTherapies&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FOSTherapies&amp;index=5&amp;md5=085476148aea4a4be49256a2e0749793\">https:\/\/x.com\/OSTherapies<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fostherapies%2F&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.instagram.com%2Fostherapies%2F&amp;index=6&amp;md5=ef7cef4236d732fbe25f5c9e7a792b59\">https:\/\/www.instagram.com\/ostherapies\/<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FOSTherapies%2F&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2FOSTherapies%2F&amp;index=7&amp;md5=5da33c0eedcc89ae787ed6950d14f084\">https:\/\/www.facebook.com\/OSTherapies\/<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fos-therapies%2F&amp;esheet=54235869&amp;newsitemid=20250409331328&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fos-therapies%2F&amp;index=8&amp;md5=3bc92e08af9142bed549ebc3f811f534\">https:\/\/www.linkedin.com\/company\/os-therapies\/<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Biotechnology Other Health Health Pharmaceutical General Health Other Science Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250409331328\/en\/2434383\/3\/OST_New_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals Company now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added NEW YORK&#8211;(BUSINESS WIRE)&#8211; OS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of the Company\u2019s lead asset OST-HER2 in the prevention of recurrence in fully-resected, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-835409","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals Company now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added NEW YORK&#8211;(BUSINESS WIRE)&#8211; OS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of the Company\u2019s lead asset OST-HER2 in the prevention of recurrence in fully-resected, &hellip; Continue reading &quot;OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T11:43:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals\",\"datePublished\":\"2025-04-09T11:43:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/\"},\"wordCount\":1100,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/\",\"name\":\"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-04-09T11:43:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Market Newsdesk","og_description":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals Company now listeria-based cancer immunotherapy world leader Expands clinical pipeline with 3 new cancer immunotherapy candidates 8 pre-clinical immunotherapy candidates targeting 30+ cancers added NEW YORK&#8211;(BUSINESS WIRE)&#8211; OS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals. The Company is now positioned as the world leader in listeria-based cancer immunotherapies, poised to become a new commercial category of immunotherapy in oncology upon approval of the Company\u2019s lead asset OST-HER2 in the prevention of recurrence in fully-resected, &hellip; Continue reading \"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-09T11:43:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals","datePublished":"2025-04-09T11:43:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/"},"wordCount":1100,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/","name":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-04-09T11:43:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250409331328r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-assets-from-ayala-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=835409"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835409\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=835409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=835409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=835409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}